Macrovascular complications
| | | | | | | | |
CAD (%)
|
45 (23.8)
|
17 (29.3)
|
9 (20.0)
|
19 (22.1)
|
0.4802
| | | |
PVD (%)
|
14 (7.5)
|
6 (10.2)
|
1 (2.3)
|
7 (8.2)
|
0.3081
| | | |
CVA/TIA (%)
|
12 (6.3)
|
7 (12.1)
|
1 (2.2)
|
4 (4.6)
|
0.1305
|
0.1336
|
0.1164
|
0.4980
|
Any macrovascular complications (%)
|
57 (30.0)
|
23 (39.0)
|
10 (22.2)
|
24 (27.9)
|
0.1539
| | | |
Microvascular complications
| | | | | | | | |
Nephropathy (%)
|
65 (35.7)
|
24 (40.7)
|
11 (25.6)
|
30 (37.5)
|
0.2635
| | | |
Retinopathy (%)
|
31 (18.8)
|
14 (25.6)
|
2 (5.1)
|
15 (21.7)
|
0.0406
|
0.0121
|
0.7080
|
0.0228
|
Neuropathy (%)
|
50 (27.3)
|
15 (25.9)
|
7 (15.9)
|
28 (34.6)
|
0.0785
|
0.2261
|
0.2735
|
0.0265
|
Any microvascular complications (%)
|
95 (53.7)
|
31 (53.5)
|
16 (37.2)
|
48 (63.2)
|
0.0243
|
0.1057
|
0.2576
|
0.0064
|
Disease status (last visit):
| | | | | | | | |
HbA1c (%)(mean, SD)
|
7.6 (1.6)
|
7.8 (1.8)
|
6.6 (0.9)
|
7.9 (1.5)
|
<0.0001
|
<0.0001
|
0.7069
|
<0.0001
|
HbA1c (IFCC units mmol/mol)
|
60
|
62
|
49
|
63
| | | | |
HbA1c ≤ 7.0% or 53 mmol/mol (%)
|
86 (46.2)
|
25 (42.4)
|
37 (84.1)
|
24 (28.9)
|
<0.0001
|
<0.0001
|
0.0964
|
<0.0001
|
Change in HbA1c (%) (mean, SD)
|
−0.90 (1.7)
|
−0.74 (1.75)
|
−1.28 (1.87)
|
−0.80 (1.69)
|
0.2480
| | | |
Weight (kg) (mean, SD)
|
94.5 (23.3)
|
94.3 (21.8)
|
88.8 (21.2)
|
97.6 (25.0)
|
0.1289
|
0.2074
|
0.4183
|
0.0495
|
Change in weight (mean, SD)
|
0.8 (5.1)
|
1.6 (5.6)
|
0.3 (5.3)
|
0.4 (4.7)
|
0.2978
| | | |
BMI
|
33.9 (7.7)
|
34.2 (7.4)
|
32.5 (7.2)
|
34.5 (8.2)
|
0.3726
| | | |
SBP (mean, SD)
|
139.2 (19.8)
|
141.7 (21.8)
|
133.4 (17.9)
|
140.5 (18.9)
|
0.0712
|
0.0390
|
0.7263
|
0.0376
|
DBP (mean, SD)
|
73.1 (9.6)
|
71.8 (9.6)
|
72.4 (10.4)
|
74.2 (9.1)
|
0.2828
| | | |
Total Chol (mean, SD)
|
4.5 (1.4)
|
4.4 (1.2)
|
4.4 (1.1)
|
4.7 (1.6)
|
0.2377
| | | |
HDL-C (mean, SD)
|
1.2 (0.3)
|
1.1 (0.3)
|
1.2 (0.3)
|
1.2 (0.3)
|
0.6053
| | | |
LDL-C (mean, SD)
|
2.3 (1.0)
|
2.4(1.0)
|
2.3 (1.0)
|
2.3 (1.0)
|
0.8984
| | | |
Triglycerides (median, QR)
|
1.8 (1.2–2.7)
|
1.7 (1.3–2.5)
|
1.8 (1.2–2.5)
|
1.9 (1.3–3.2)
|
0.3467
| | | |
TC:HDL-C (mean, SD)
|
4.1 (1.4)
|
4.03 (1.2)
|
3.82 (1.2)
|
4.31 (1.6)
|
0.1874
| | | |
Smoker (%)
|
33 (18.8)
|
6 (10.9)
|
7 (16.3)
|
20 (25.6)
|
0.0897
|
0.4367
|
0.0349
|
0.2365
|
Last visit medications:
| | | | | | | | |
On insulin (%)
|
75 (38.9)
|
37 (62.7)
|
7 (15.2)
|
31 (35.2)
|
<0.0001
|
<0.0001
|
0.0011
|
0.0147
|
On ACE-I/ARB (%)
|
144 (74.6)
|
48 (81.4)
|
33 (71.7)
|
63 (71.6)
|
0.3604
| | | |
On ASA (%)
|
94 (48.7)
|
37 (62.7)
|
20 (43.5)
|
37 (42.1)
|
0.0351
|
0.0497
|
0.0140
|
0.8734
|
On Statin (%)
|
146 (75.7)
|
49 (83.1)
|
37 (80.4)
|
60 (68.2)
|
0.0825
|
0.7297
|
0.0436
|
0.1320
|
Clinic activity
| | | | | | | | |
Median duration of follow-up (months)
|
16 (6 to 31)
|
33(31 to 35)
|
10 (4 to 18)
|
9 (5 to 17)
|
<0.0001
|
<0.0001
|
<0.0001
|
0.8827
|
% of MD visits where meds changed (Mean, SD)
|
48.7 (30.0)
|
55.2 (23.1)
|
34.4 (25.7)
|
51.8 (33.9)
|
0.0007
|
<0.0001
|
0.5037
|
0.0027
|
% of patient encounters that were no-shows (Median, IQR)
|
14.3 (0 to 33.3)
|
8.3 (0 to 16.7)
|
0 (0 to 14.3)
|
30 (13.8 to 50.0)
|
<0.0001
|
0.1112
|
<0.0001
|
<0.0001
|
Number of visits with MD (mean, SD)
|
4.9 (3.1)
|
8.1 (2.8)
|
3.3 (1.9)
|
3.7 (2.0)
|
<0.0001
|
<0.0001
|
<0.0001
|
0.2907
|
Number of visits with RN (mean, SD)
|
2.5 (2.1)
|
3.7 (2.6)
|
2.1 (1.7)
|
2.0 (1.7)
|
<0.0001
|
0.0006
|
<0.0001
|
0.6919
|
Number of visits with RD (mean, SD)
|
2.4 (2.0)
|
3.5 (2.5)
|
2.2 (1.9)
|
1.7 (1.3)
|
<0.0001
|
0.0036
|
<0.0001
|
0.1053
|